HomeIn vivo Formulation Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Featured Products

E1051 MRTX1133 MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.
E1474 BI-2865 BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce
E1549 AZD0095 AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib.
E1858 RMC-7977 RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).
E1908 HRO761 HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells.
S1067 SB431542 SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.
S1077 SB202190 SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
S2619 MG132 MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.
S7085 IWP-2 IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
S7507 LDN-193189 Dihydrochloride LDN-193189 (DM3189) 2HCl is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.
S7609 GW4869 GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.
S7692 A-83-01 A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared.
S7803 Gsk484 Hydrochloride GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
S7809 MCC950 Sodium MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
S8383 S63845 S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.
S8740 A-485 A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
S8843 AZD7648 AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases.
S8874 PLX5622 PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.
S9870 STM2457 STM2457 is a highly potent and selective first-in-class catalytic inhibitor of RNA Methyltransferase METTL3 with an IC50 of 16.9 nM. STM2457 is highly specific for METTL3 and showed no inhibition of other RNA methyltransferases.

New Products Click to View More

E8324 GE11 GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research.
E0850 DPhPC DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties.
F2691 CHOP Antibody [C21N8] CHOP,DDIT3,DDIT3/GADD153/CHOP,GADD153/CHOP
F1374 HSL Antibody [M23F5] Hormone sensitive lipase/HSL,HSL
F1507 CA9 Antibody [J19A24] CA9,Carbonic Anhydrase 9/CA9,Carbonic Anhydrase IX/CA9
F1545 Sp7/Osterix Antibody [J12J9] OSX,Sp7 / Osterix
F1536 CD11b + CD11c Antibody [C8C21] CD11b + CD11c,CD11b/c
F2031 VSV-G tag Antibody [N12B16] VSV Glycoprotein,VSV-G tag
F1926 α-adaptin A Antibody [D21J17] alpha Adaptin,alpha-Adaptin,α-Adaptin 1/2
F2201 Phospho-SHP2 (Tyr542) Antibody [J17K6] Phospho-SHP-2 (Tyr542),SHP2 (phospho Y542)
F2358 Phospho-STAT1 (Ser727) Antibody [F23C16] Phospho-Stat1 (Ser727),STAT1 (phospho S727)
F2238 Influenza A Virus M2 Protein Antibody [L21L24] Influenza A M2,Influenza A Virus M2 Protein
F3018 IFN-γ Antibody [A4P20] IFN-γ,Interferon gamma
F3034 TIM-3 Antibody [N19P14] TIM 3,TIM-3
F2530 ZO1 tight junction protein Antibody [A24G22] Tight Junction Protein 1,ZO-1,ZO1 tight junction protein
F2353 VEGFB Antibody [E11E24] VEGFB,VEGF-B
F2948 smooth muscle Myosin heavy chain 11 Antibody [J22F5] MYH11,Myosin (Smooth),smooth muscle Myosin heavy chain 11
F1564 Mucin 5AC Antibody [L15D9] Blood Group Lewis b,MUC5AC,Mucin 5AC,Mucin 5AC/MUC5AC,Mucin Gastric,Mucin MUC5AC
F2693 Desmoglein 1 Antibody [L24P16] Desmoglein 1,Desmoglein 1/DSG1
F2741 uPA Antibody [F9E24] uPA,Urokinase
F2743 Ferritin Light Chain Antibody [N23F20] Ferritin Light Chain,FTL
F0312 ULK1 Antibody [A14P9] Atg1/ULK1,ULK1
F0406 Phospho-cdc25C (Ser216) Antibody [D12E13] Cdc25C (phospho S216),Phospho-cdc25C (Ser216)
F3421 PF4 Antibody [L7F2] CXCL4/PF4,PF4
F3588 Myosin Light Chain 2 Antibody [C23E15] MYL9,Myosin Light Chain 2
F3669 Hsp22/HSPB8 Antibody [E11C19] Hsp22/HSPB8,HSPB8/HSP22
F3428 Chromogranin A Antibody [C10M7] CHGA,Chr-A,Chromogranin A
F3439 RPL10A Antibody [D11A13] Ribosomal Protein L10a,RPL10A
F3218 5T4 Antibody [J8G16] 5T4,TPBG/5T4
F3292 PCB Antibody [K5L1] PCB,Pyruvate Carboxylase
F3647 Phospho-EGFR (Tyr992) Antibody [F20E14] EGFR (phospho Y992),Phospho-EGF Receptor (Tyr992)
F3783 Phospho-JAK1 (Tyr1034 + Tyr1035) Antibody [F22D15] JAK1 (phospho Y1034 + Y1035),Phospho-Jak1(Tyr1034/1035)
F2856 APG5L/ATG5 Antibody [K12K17] APG5/ATG5,APG5L/ATG5,Atg5
F2860 Phospho-NAK/TBK1 (Ser172) Antibody [G18L12] NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172)
F2686 Acetyl-α-Tubulin (Lys40) Antibody [F22D16] acetyl-alpha tubulin,Acetyl-alpha Tubulin (Lys40),Acetylated Tubulin,Acetyl-α-Tubulin (Lys40),alpha Tubulin (acetyl K40),alpha Tubulin acetyl K40,Tubulin, Acetylated
E8323 Emeramide Emeramide functions as a thiol-based redox antioxidant and chelates heavy metals.
E0848 Pinealon Pinealon is a tripeptide exhibiting neuroprotective effects. This peptide inhibits reactive oxygen species (ROS) buildup and blocks ERK 1/2 activation. It enhances functional activity of key brain tissue cellular components while decreasing spontaneous cell death rates. Studies demonstrate Pinealon's protective effects against prenatal hyperhomocysteinemia in rat offspring.
E6646 BMS-986260 BMS-986260 is an orally active immuno-oncology agent that inhibits TGFβR1 with an IC50 of 1.6 nM. It shows selectivity for TGFβR1 compared to TGFβR2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGFβ-induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively.
E6560 naperiglipron Naperiglipron (LY3549492) (Example 2) acts as a glucagon-like peptide 1 receptor (GLP-1R) agonist, exhibiting an EC50 of 1.14 nM at hGLP-1R. In GLP-1R knock-in mouse models, it reduces blood glucose levels. The compound shows PDE10A1 enzyme inhibitory activity (IC50: 7.43 μM) and displays weak hERG inhibition. Naperiglipron has potential applications in type II diabetes mellitus (T2DM) and obesity studies.
E6638 VS-7375 (GFH375) VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model.
E6517 PKN1 PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumor cell migration and related physiological processes.
E6521 HRS‑5346 Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders.
E6578 AS1708727 AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK.
E6498 Atebimetinib (IMM-1-104) Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects.
E6639 Auceliciclib (AU3-14,Ulecaciclib ) Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with Ki values of 0.62 μM for CDK2/Cyclin A, 0.2 nM for CDK4/Cyclin D1, 3 nM for CDK6/Cyclin D3, and 0.63 μM for CDK7/Cyclin H. This compound demonstrates blood-brain barrier penetration and favorable pharmacokinetic properties.
P1231 Mazdutide (IBI362, LY330567) Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D).
E6643 SS-3091 SS-3091 is a pan-KRas inhibitor that targets the interaction interfaces of KRas. By destabilizing the ARaf/KRas complex, it modulates downstream signaling pathways. This compound exhibits activity against KRas G12D, G12C, G12V, and G12S mutants in multiple cancer cell lines.
E5927 Mito-LND (Mito-Lonidamine) Mito-LND (Mito-Lonidamine) is an orally administered mitochondria-targeted compound that inhibits oxidative phosphorylation (OXPHOS). This agent reduces mitochondrial bioenergetics, promotes reactive oxygen species generation, and triggers autophagic cell death in lung cancer cells.
E6511 ADT-1004 ADT-1004 is a RAS inhibitor that may be investigated for Ras-mediated diseases.
P1262 Eloralintide (LY-3841136) Eloralintide (LY 3841136) is an AMYR agonist with potential applications in type 2 diabetes and obesity research.